MetaCap

Lantheus (LNTH) vs Myriad Genetics (MYGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lantheus (LNTH) has outperformed Myriad Genetics (MYGN) over the past year, gaining 82.9% versus a loss of 26.0%. Over five years, LNTH leads with a +266.1% price change compared with -79.5% for MYGN. Lantheus is the larger company by market cap ($6.68 billion vs $523.7 million), about 12.7 times the size.

Lantheus converts more of its revenue into profit, with a net margin of 15.2% versus -44.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LNTH+82.91%MYGN-26.02%
+107%+19%-69%
Nov 21, 20251 yearNov 20, 2026
LNTH+255.87%MYGN-80.54%
+351%+120%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LNTH versus MYGN key metrics
MetricLNTHMYGN
Share price$102.10$5.46
Market cap$6.68B$523.74M
1-day change0.00%-1.44%
YTD return+53.42%-11.22%
1-year return+82.91%-26.02%
5-year return+266.08%-79.48%
P/E ratio (TTM)25.40—
Forward P/E15.34—
EPS (TTM)$4.02$-1.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.54B$824.50M
Revenue growth (YoY)+0.50%-1.56%
Net income (latest FY)$233.56M$-365.90M
Gross margin61.10%69.93%
Operating margin20.16%-46.96%
Net margin15.15%-44.38%
52-week high$111.86$8.09
52-week low$54.94$2.74
Distance from 52-week high-8.73%-32.51%
Analyst consensusholdhold
Avg. price target upside+3.81%+8.06%
Average volume1.02M2.26M
Shares outstanding65.40M95.92M
Employees1,1932,700
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Lantheus is about 12.7 times larger than Myriad Genetics by market value ($6.68B vs $523.74M).
  • LNTH has outperformed MYGN by 108.9 percentage points over the past year.
  • Lantheus is more profitable, keeping 15.2 cents of every revenue dollar as net income versus -44.4 cents for Myriad Genetics.

About Lantheus

LNTH stock →

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees

About Myriad Genetics

MYGN stock →

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees

LNTH vs MYGN FAQ

Which is bigger, Lantheus or Myriad Genetics?

Lantheus (LNTH) is larger, with a market capitalization of $6.68B compared with $523.74M for Myriad Genetics (MYGN).

Which stock has performed better over the past year, LNTH or MYGN?

LNTH returned +82.91% over the past 12 months, compared with -26.02% for MYGN (price return, excluding dividends). Past performance does not predict future results.

Are Lantheus and Myriad Genetics in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons